Transdermal testosterone substitution therapy for male hypogonadism.
A transdermal therapeutic system (TTS) for administration of testosterone was tested in healthy and hypogonadal men. To ensure adequate absorption, a testosterone-loaded film was applied to the scrotal skin. The TTS was designed to last for 22 h; over this time serum testosterone levels in normal men were moderately increased, with concentration curves almost parallel to basal levels. Seven hypogonadal patients also responded to TTS testosterone; serum testosterone levels were in the normal range during a 12-week treatment period. There were no side-effects. TTS testosterone offers a new approach to androgen substitution therapy.
D000279:Administration, Cutaneous; D000328:Adult; D002940:Circadian Rhythm; D004341:Drug Evaluation; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy*; D008297:Male; D013739:Testosterone / Q000008:administration & dosage* / Q000097:blood
D013739:Testosterone